Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 11, 2007, Pages 829-835

  Lee, Sung Sook ^a   Kim, Sung Bae ^a   Park, Seung Il ^a   Kim, Yong Hee ^a   Ryu, Jin Sook ^a   Song, Ho Yong ^a   Shin, Ji Hoon ^a   Jung, Hwoon Yong ^a   Lee, Gin Hyug ^a   Choi, Kee Don ^a   Cho, Kyung Ja ^a   Kim, Jong Hoon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Capecitabine; Cisplatin; Esophageal cancer

Indexed keywords

CAPECITABINE; CISPLATIN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS PERFORATION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; RADIATION DOSE; SURVIVAL TIME; THROMBOCYTOPENIA; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 37149009185     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym117     Document Type: Article

References (31)

1. TNM Classification of Malignant Tumors, 5th edn. New York: Wiley-Liss, 1997.
2. Douple EB, Richmond RC. A review interactions between platinum coordination complexes and ionizing radiation: Implications for cancer therapy. In Cisplatin: Current status and New Developments, Prestayko AW, Crooke ST, Karter SK, editors. Orland, FL: Academic Press, 1980;125-47.
3. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986;83:8923-5.
4. Byfield JE. Combined modality infusional chemotherapy with radiation. In: Cancer Chemotherapy by infusion, Lokich JJ editor, 2nd edn. Chicago, IL: Percepts Press, 1990;521-51.
5. Kim MO, Hong ES, Chai JY, Leem JM, You IY, Kim WD, Park WY, Kim ST, Lee K.H. Concurrent FP (5-fluorouracil, cisplatin) chemoradiothempy for patients with esophageal cancer. Cancer Res Treat 2003;35:330-4.
6. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbarnate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer fissue. Eur J Cancer 1998;34:1274-81.
7. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmac 2000;45:291-7.
8. MaEvoy GK. AHFS Drug Information. Bethesda, MD: American Society of Health System Pharmacists Inc., 2001;886-91.
9. Sawada. N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka. H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-53.
10. Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002;53:675-9.
11. Kang YK, Kang WK, Shin DB, Chem J, Xong J, Wang J, et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. Proc Am Soc Clin Oncol 2006;24:18S (abstract LBA 4018).
12. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002;13:1893-8.
13. Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003;14:1115-20.
14. Kim SB, Park SI, Kim JK Jung HY, Lee GH, Park JH, et al. A phase II trial of preoperative one cycle of induction chemotherapy capeciatine (CAP), CDDP. followed concurrent chemoradiation (CRT) in patients (pts) with resectable esophageal cancer. Proc Am Soc Clin Oncol 2005;23:16S (abstrac 4063).
15. Ajani J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 2006;107:221-31.
16. Lee J, Im Y, Kang J, et al. Phase II study of capecitabine and cisplatin as first-line therapy in patients with recurrent or metastatic esophageal carcmoma. Proc Am Soc Clin Oncol 2005;23:362s (abstract 4221).
17. American Joint Committee on Cancer (AJCC) staff. AJCC Cancer Staging Manual, 6th edn. New York: Wiley-Liss, 2002.
18. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-20.
19. Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/ or M1 lymph node squamous cel carcinoma of the esophagus. J Clin Oncol 1999;17:2915-21.
20. Steup WH, De Leyn P, Deneffe G., Van Raemdonck D, Coosemans W, Lerut T. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996;111:85-95.
21. Korst RJ, Rusch VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660-70.
22. Shim YM, Choi YS, Kim KK. Prognosis after surgical resection of M1a/M1b esophageal squamous cell carcinoma. J Korean Med Sci 2005;20:229-31.
23. Akiyama H, Tsurumaru M, Udagawa H, et al. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-73.
24. Nishimaki T, Suzuki T, Suzuki S, et al. Outcomes of extended radical esophagectomy for thoracic esophageal cance. J Am Coll Surg 1998;186:306-12.
25. Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for radical lymphadenectomy for esophageal, cancer. Ann Surg 1995;222:654-62.
26. Tachibana M, Kumar D, Kinugasa S, Kotoh T, et al. Esophageal cancer with distant lymph node metastasis. J Clin Gastroenterol 2000;31: 318-22.
27. Rice TW, Blackstone EH, Rybicki LA, Adelstein DJ, Murthy SC, DeCamp MM, Goldblum JR. Refining esophageal cancer staging. J Thorac Cardiovasc Surg 2003;125:1103-13.
28. Christie NA, Rice TW, DeCamp MM, Goldblum JR, Adelstein DJ, Zuccaro G, Jr, et al. M1a/M1b esophageal carcinoma: Clinical relevance. J Thorac Cardiovasc Surg 1999;118:900-7.
29. Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM, Jr. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006;17:29-34.
30. Lorenzen S, Duyster J, Lersch C, Delius S, Lang B, et al. Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): Final results of the phase II DACAPO trial. Proc Am Soc Clin Oncol 2005;23:16s (abstract 4142).
31. Jatoi A, Foster N, Johnson P et al. Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer: A multi-institutional study from the North Central Cancer Treatment Group. Dis Esophagus 2004;17:292-6.